Table 2.

Select ongoing clinical trials in frontline treatment of advanced HCC.

Clinical trial identifier	Phase	Agent(s)	Primary endpoint(s)	Setting	Recruitment status
CheckMate 9DW (NCT04039607)	3	Nivolumab + ipilimumab versus sorafenib versus lenvatinib	OS	First line	Active, not recruiting
LEAP-002 (NCT03713593)	3	Lenvatinib + pembrolizumab versus lenvatinib + placebo	PFS, OS	First line	Active, not recruiting
RATIONALE 301 (NCT03412773)	3	Tislelizumab versus sorafenib	OS, Safety	First line	Active, not recruiting
NCT03680508	2	Cobolimab (anti-TIM-3 Ab) + dostarlimab	ORR	First line	Recruiting
NCT03764293	3	Apatinib + camrelizumab versus sorafenib	PFS, OS	First line	Recruiting
DEDUCTIVE (NCT03970616)	1b/2	Tivozanib + durvalumab	Safety	First line and second line	Recruiting
NCT04183088	2	Regorafenib + tislelizumab	Safety, ORR, PFS	First line	Recruiting
GOING (NCT04170556)	½	Regorafenib followed by nivolumab	Safety	Second line	Recruiting
RENOBATE (NCT04310709)	2	Regorafenib + nivolumab	ORR	First line	Recruiting
REGSIN (NCT04718909)	2	Regorafenib + sintilimab	PFS	Second line	Recruiting
ORIENT-32 (NCT03794440)	2/3	Sintilimab + IBI305 versus sorafenib	PFS, OS	First line	Active, not recruiting
NCT04050462	II	Cabiralizumab + nivolumab versus nivolumab versus nivolumab + BMS-986253	ORR	First line	Recruiting

HCC, hepatocellular carcinoma; ORR, overall response rate; OS, overall survival; PFS,